Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Change in Acquisitions & Divestments (2017 - 2025)

Lisata Therapeutics (LSTA) has disclosed Change in Acquisitions & Divestments for 8 consecutive years, with $5.1 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Acquisitions & Divestments fell 43.8% year-over-year to $5.1 million, compared with a TTM value of $37.4 million through Sep 2025, down 47.55%, and an annual FY2024 reading of $69.1 million, down 36.41% over the prior year.
  • Change in Acquisitions & Divestments was $5.1 million for Q3 2025 at Lisata Therapeutics, up from $4.6 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $34.4 million in Q1 2023 and bottomed at $4.6 million in Q2 2025.
  • Average Change in Acquisitions & Divestments over 3 years is $18.4 million, with a median of $15.4 million recorded in 2023.
  • The sharpest move saw Change in Acquisitions & Divestments decreased 14.83% in 2024, then tumbled 78.37% in 2025.
  • Year by year, Change in Acquisitions & Divestments stood at $15.4 million in 2023, then fell by 14.83% to $13.1 million in 2024, then crashed by 60.76% to $5.1 million in 2025.
  • Business Quant data shows Change in Acquisitions & Divestments for LSTA at $5.1 million in Q3 2025, $4.6 million in Q2 2025, and $14.5 million in Q1 2025.